A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. (Q54718176)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. |
scientific article |
Statements
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study (English)
Janice P Dutcher
Uday B Dandamudi
Musie Ghebremichael
Jeffrey A Sosman
Joseph I Clark
David F McDermott
Michael B Atkins
Walter J Urba
Meredith M Regan
Todd S Crocenzi
Brendan D Curti
Ulka N Vaishampayan
Nancy A Crosby
Kim A Margolin
Marc S Ernstoff
1 November 2013